HK1200274A1 - Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate - Google Patents
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate Download PDFInfo
- Publication number
- HK1200274A1 HK1200274A1 HK15100236.7A HK15100236A HK1200274A1 HK 1200274 A1 HK1200274 A1 HK 1200274A1 HK 15100236 A HK15100236 A HK 15100236A HK 1200274 A1 HK1200274 A1 HK 1200274A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glatiramer acetate
- single nucleotide
- nucleotide polymorphisms
- subject
- clinical response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545282P | 2011-10-10 | 2011-10-10 | |
| US61/545,282 | 2011-10-10 | ||
| US201261636560P | 2012-04-20 | 2012-04-20 | |
| US61/636,560 | 2012-04-20 | ||
| PCT/US2012/059352 WO2013055683A1 (en) | 2011-10-10 | 2012-10-09 | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1200274A1 true HK1200274A1 (en) | 2015-08-07 |
Family
ID=48082342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15100236.7A HK1200274A1 (en) | 2011-10-10 | 2012-10-09 | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8815511B2 (enExample) |
| EP (1) | EP2765857A4 (enExample) |
| JP (1) | JP2014530819A (enExample) |
| KR (1) | KR20140101730A (enExample) |
| CN (1) | CN103957705A (enExample) |
| AR (1) | AR088294A1 (enExample) |
| AU (1) | AU2012323345A1 (enExample) |
| BR (1) | BR112014008752A2 (enExample) |
| CA (1) | CA2851510A1 (enExample) |
| EA (1) | EA201490749A1 (enExample) |
| HK (1) | HK1200274A1 (enExample) |
| IL (1) | IL231723A0 (enExample) |
| MX (1) | MX2014004309A (enExample) |
| TW (1) | TW201326399A (enExample) |
| UY (1) | UY34380A (enExample) |
| WO (1) | WO2013055683A1 (enExample) |
| ZA (1) | ZA201403049B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| WO2014058976A2 (en) * | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| JP6432974B2 (ja) * | 2014-06-20 | 2018-12-05 | 国立大学法人東北大学 | ＴａｇＳＮＰの選択方法、選択用コンピュータシステム、及び、選択用ソフトウエア |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| WO2016172124A1 (en) * | 2015-04-21 | 2016-10-27 | Teva Pharmaceutical Industries Ltd. | Select single nucleotide polymorphisms predictive of response to glatiramer acetate |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| US11396825B2 (en) * | 2017-08-14 | 2022-07-26 | General Electric Company | Turbine diagnostic feature selection system |
| JP2022506192A (ja) * | 2018-11-01 | 2022-01-17 | アイ２ディーエックス インコーポレイテッド | 治療標的特定のためのインテリジェントシステム及び方法 |
| CA3141888A1 (en) * | 2019-05-30 | 2020-12-03 | The University Of Newcastle | A method of treatment or prophylaxis |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| ES2408706T3 (es) | 1998-09-25 | 2013-06-21 | Yeda Research And Development Co., Ltd. | Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| HK1054507B (zh) | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| MXPA02008023A (es) | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| CA2411536A1 (en) | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1459065B1 (en) | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| WO2005075022A2 (en) | 2004-01-30 | 2005-08-18 | Decode Genetics Ehf. | Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment |
| US20080293750A1 (en) | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| US20060019269A1 (en) | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| WO2004060265A2 (en) | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| CA2525771A1 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| US20050064483A1 (en) | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
| CN1886506B (zh) | 2003-09-29 | 2012-05-30 | 中外制药株式会社 | 在nk细胞中表达的蛋白质 |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| US20100216863A1 (en) | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US20050266410A1 (en) | 2004-05-19 | 2005-12-01 | Emily Walsh | Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes |
| NZ578727A (en) | 2004-06-25 | 2011-03-31 | Brigham & Womens Hospital | Proteosome compositions and methods for treating neurological disorders |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| DK1799703T3 (da) | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| DE602005016292D1 (de) | 2004-10-29 | 2009-10-08 | Sandoz Ag | Verfahren zur herstellung von glatiramer |
| US20060172942A1 (en) | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| RS52867B (sr) | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze |
| US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| SI2046817T1 (sl) | 2006-07-05 | 2010-04-30 | Momenta Pharmaceuticals Inc | Izboljšani postopek za pripravo kopolimera-1 |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
| WO2009070298A1 (en) | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| US20090177487A1 (en) | 2008-01-07 | 2009-07-09 | Tera Eerkes | Methods for Assessing Genetic Compatibility |
| EP2307544A4 (en) | 2008-06-13 | 2012-09-05 | Prognomix Inc | GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES |
| EP2310533A4 (en) | 2008-07-04 | 2012-03-14 | Axial Biotech Inc | GENETIC MARKERS ASSOCIATED WITH DEGENERATIVE DISC DISEASE AND USES THEREOF |
| WO2010103292A2 (en) * | 2009-03-12 | 2010-09-16 | Brainco Biopharma S.L. | A genotyping tool for improving the prognostic and clinical management of ms patients |
| WO2010118210A1 (en) | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| PT2275086E (pt) | 2009-07-15 | 2012-05-18 | Teva Pharma | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| US8853378B2 (en) | 2009-10-09 | 2014-10-07 | Georgetown University | Polynucleotides that home to atherosclerotic plaque |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| WO2014058976A2 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| EA201591187A1 (ru) | 2012-12-21 | 2016-03-31 | Тева Фармасьютикал Индастриз Лтд. | Пероральная трансмукозальная доставка ацетата глатирамера |
| MX2015007678A (es) | 2012-12-21 | 2015-09-07 | Teva Pharma | Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. |
| JP2016504039A (ja) | 2013-01-04 | 2016-02-12 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテート関連医薬品の特性決定 |
| CN105188751A (zh) | 2013-03-12 | 2015-12-23 | 泰华制药工业有限公司 | 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2012
- 2012-10-09 MX MX2014004309A patent/MX2014004309A/es unknown
- 2012-10-09 WO PCT/US2012/059352 patent/WO2013055683A1/en not_active Ceased
- 2012-10-09 HK HK15100236.7A patent/HK1200274A1/xx unknown
- 2012-10-09 AU AU2012323345A patent/AU2012323345A1/en not_active Abandoned
- 2012-10-09 JP JP2014535787A patent/JP2014530819A/ja not_active Withdrawn
- 2012-10-09 US US13/648,135 patent/US8815511B2/en not_active Expired - Fee Related
- 2012-10-09 EP EP12840243.5A patent/EP2765857A4/en not_active Withdrawn
- 2012-10-09 TW TW101137349A patent/TW201326399A/zh unknown
- 2012-10-09 EA EA201490749A patent/EA201490749A1/ru unknown
- 2012-10-09 CA CA2851510A patent/CA2851510A1/en not_active Abandoned
- 2012-10-09 CN CN201280058097.0A patent/CN103957705A/zh active Pending
- 2012-10-09 KR KR1020147012550A patent/KR20140101730A/ko not_active Withdrawn
- 2012-10-09 BR BR112014008752A patent/BR112014008752A2/pt not_active IP Right Cessation
- 2012-10-10 UY UY0001034380A patent/UY34380A/es not_active Application Discontinuation
- 2012-10-10 AR ARP120103778A patent/AR088294A1/es unknown
-
2014
- 2014-03-26 IL IL231723A patent/IL231723A0/en unknown
- 2014-04-25 ZA ZA2014/03049A patent/ZA201403049B/en unknown
- 2014-08-25 US US14/467,954 patent/US9499868B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ624258A (en) | 2016-09-30 |
| EP2765857A4 (en) | 2015-12-09 |
| MX2014004309A (es) | 2015-07-06 |
| US8815511B2 (en) | 2014-08-26 |
| ZA201403049B (en) | 2015-09-30 |
| UY34380A (es) | 2013-05-31 |
| EP2765857A1 (en) | 2014-08-20 |
| WO2013055683A1 (en) | 2013-04-18 |
| IL231723A0 (en) | 2014-05-28 |
| KR20140101730A (ko) | 2014-08-20 |
| CA2851510A1 (en) | 2013-04-18 |
| US9499868B2 (en) | 2016-11-22 |
| AU2012323345A1 (en) | 2014-05-22 |
| US20130123189A1 (en) | 2013-05-16 |
| CN103957705A (zh) | 2014-07-30 |
| EA201490749A1 (ru) | 2014-09-30 |
| BR112014008752A2 (pt) | 2017-04-25 |
| TW201326399A (zh) | 2013-07-01 |
| JP2014530819A (ja) | 2014-11-20 |
| US20150045306A1 (en) | 2015-02-12 |
| AR088294A1 (es) | 2014-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016005003A (es) | Marcadores geneticos predictivos de respuesta al acetato de glatiramero. | |
| WO2014058976A3 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
| BR112014008752A2 (pt) | polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero | |
| AU2018260866A1 (en) | Selective reduction of allelic variants | |
| WO2012174338A3 (en) | Method of selecting therapeutic indications | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| WO2009108856A3 (en) | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof | |
| WO2013074974A3 (en) | Modified rnai agents | |
| DK1984357T3 (da) | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme | |
| WO2011041729A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| WO2011017350A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX347871B (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. | |
| JP2014501492A5 (enExample) | ||
| WO2008088861A3 (en) | Gene polymorphisms predictive for dual tki therapy | |
| WO2013056087A3 (en) | Compositions and methods for treating and preventing coronary heart disease | |
| HK1200120A1 (en) | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells | |
| EA201270574A1 (ru) | Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний | |
| WO2009036100A3 (en) | Prediction of qt prolongation based on snp genotype | |
| WO2008112903A3 (en) | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes | |
| EP3238726A3 (en) | Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone | |
| NZ604125A (en) | Prediction of hcv viral kinetics in interferon-free treatment | |
| CL2013000709A1 (es) | Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10). | |
| WO2012091308A3 (ko) | 폴리카보네이트-폴리실록산 공중합체 및 그의 제조 방법 | |
| EP2099909A4 (en) | METHOD FOR DETERMINING THE HAPLOTYPE OF MULTIPLE ALLELIC GENES |